Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Endo restructures, lowers guidance

Endo Health Solutions Inc. (NASDAQ:ENDP) said it will reduce headcount by about 15% worldwide as part of a plan to reduce

Read the full 211 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE